NCT01999114View on ClinicalTrials.gov

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

328

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions

ECG Effects

Interventions

DRUG

Buprenorphine transdermal patch

Buprenorphine patch applied transdermally

DRUG

Naltrexone tablet

Naltrexone tablet; 1 tablet taken orally every 12 hours

DRUG

Placebos (for TDS and for naltrexone and for moxifloxacin)

Matching placebos

DRUG

Moxifloxacin tablet

Moxifloxacin tablet; 1 tablet taken orally on Days 6, 13 and 17

Trial Locations (1)

78744

PPD Phase I Clinic, Austin

All Listed Sponsors

lead

Purdue Pharma LP

INDUSTRY

NCT01999114 - The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers | Biotech Hunter | Biotech Hunter